Regdanvimab (RegkironaTM). HTA ID: 21065

Assessment Status Rapid Review Complete
HTA ID 21065
Drug Regdanvimab
Brand RegkironaTM
Indication For the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Assessment Process
Rapid review commissioned 14/12/2021
Rapid review completed 10/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of regdanvimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.